Indaptus shares surge 12% intraday after strategic pivot to public shell with $6M investment from David E. Lazar.

Indaptus Therapeutics surged 12% intraday following its strategic pivot to a public shell company after discontinuing its lead asset, Decoy20, and securing a $6 million preferred stock investment from David E. Lazar. The shift to a reverse merger-focused model, coupled with Lazar’s 96.4% ownership stake, positioned the company as a potential acquisition vehicle, attracting speculative interest. Despite reporting a $20.8 million net loss for 2025 and facing significant dilution risks, the strategic realignment and liquidity infusion created short-term optimism among investors betting on a successful M&A outcome.